| Cancer immunomodulation using bispecific aptamers BJ Thomas, D Porciani, DH Burke Molecular Therapy-Nucleic Acids 27, 894-915, 2022 | 24 | 2022 |
| Lysoptosis is an evolutionarily conserved cell death pathway moderated by intracellular serpins CJ Luke, S Markovina, M Good, IE Wight, BJ Thomas, JM Linneman, ... Communications Biology 5 (1), 47, 2022 | 13 | 2022 |
| CemOrange2 fusions facilitate multifluorophore subcellular imaging in C. elegans BJ Thomas, IE Wight, WYY Chou, M Moreno, Z Dawson, A Homayouni, ... PLoS One 14 (3), e0214257, 2019 | 13 | 2019 |
| Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer BJ Thomas, C Guldenpfennig, Y Guan, C Winkler, M Beecher, M Beedy, ... Molecular Therapy-Nucleic Acids 34, 2023 | 3 | 2023 |
| Multiplexed In Vivo Screening Using Barcoded Aptamer Technology to Identify Oligonucleotide-Based Targeting Reagents BJ Thomas, C Guldenpfennig, MA Daniels, DH Burke, D Porciani nucleic acid therapeutics, 2024 | 1 | 2024 |
| Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations BJ Thomas, SZ Awan, T Joshi, MA Daniels, D Porciani, DH Burke-Aguero bioRxiv, 2024.04. 01.587576, 2024 | | 2024 |
